Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

rAAt (dermatological) Arriva/ProMetic.

William M Brown1

  • 1Paddock Laboratories Inc, 3940 Quebec Avenue North, Minneapolis, MN 55427, USA. wbrown@paddocklabs.com

Current Opinion in Molecular Therapeutics
|March 2, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcatheter Aortic Valve Replacement in Patient With Extensive Aortic Dissection: Role of "Balloon Flossing".

Journal of the Society for Cardiovascular Angiography & Interventions·2025
Same author

Impact of low testing numbers on chronic wasting disease apparent prevalence.

Prion·2025
Same author

The Value and Challenges of an Ambulatory Intermediate Care Clinic: A Mixed-Methods Analysis.

The Journal of ambulatory care management·2025
Same author

Improved performance of nucleic acid-based assays for genetically diverse norovirus surveillance.

Applied and environmental microbiology·2023
Same author

Version or High Forceps, Which and When?

Buffalo medical journal·2023
Same author

The Impact of Variation in the Toll-like Receptor 3 Gene on Epizootic Hemorrhagic Disease in Illinois Wild White-Tailed Deer (<i>Odocoileus virginianus</i>).

Genes·2023

Arriva Pharmaceuticals and ProMetic Life Sciences are developing a topical gel of recombinant alpha1-antitrypsin (rAAT). This therapy is in Phase II trials for atopic dermatitis and other skin disorders, with preclinical research for psoriasis and otitis media.

Area of Science:

  • Dermatology and Pharmaceutical Development
  • Biologics and Protein Therapeutics

Background:

  • Atopic dermatitis and severe dermatological disorders represent significant unmet medical needs.
  • Recombinant alpha1-antitrypsin (rAAT) possesses anti-inflammatory properties with potential therapeutic applications in skin conditions.
  • Topical formulations offer a targeted delivery approach for dermatological treatments.

Purpose of the Study:

  • To evaluate the efficacy and safety of a topical gel formulation of rAAT.
  • To explore the potential of rAAT in treating inflammatory skin conditions like atopic dermatitis and psoriasis.
  • To investigate rAAT for other inflammatory conditions such as otitis media.

Main Methods:

  • Phase II clinical trials are underway to assess the topical rAAT gel in patients with atopic dermatitis.

Related Experiment Videos

  • Preclinical investigations are being conducted to explore rAAT's utility in psoriasis and otitis media models.
  • The study involves the development of a novel gel formulation for topical drug delivery.

    • Main Results:

    • The topical rAAT gel formulation is currently in Phase II clinical trials for atopic dermatitis.
    • Preclinical data suggests potential efficacy for rAAT in other inflammatory skin conditions.
    • Further research is ongoing to determine the full therapeutic scope of rAAT.

    Conclusions:

    • Topical rAAT gel shows promise as a novel treatment for atopic dermatitis and potentially other dermatological disorders.
    • rAAT is being explored for its anti-inflammatory effects in various preclinical models.
    • Ongoing clinical and preclinical studies will define the therapeutic role of rAAT in inflammatory conditions.